martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 23, 2026

Cardinal Health and FMC Corporation have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
Cardinal Health and FMC Corporation have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – February 23, 2026 – Zacks Equity Research shares Cardinal Health CAH as the Bull of the Day and FMC Corporation FMC as the Bear of the Day…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cardinal Health expects specialty products to generate more than $50 billion in sales during current fiscal year

    80% confidence
  • FMC Corporation is a Zacks Rank #5 (Strong Sell) and expected to underperform

    80% confidence
  • JPMorgan plans to open more than 160 new branches across more than 30 U.S. states in 2026

    80% confidence
  • Cardinal Health is a Zacks Rank #1 (Strong Buy) and expected to outperform the market

    80% confidence
  • Approximately half of a stock's price appreciation is due to its industry grouping, with top 50% of Zacks Ranked Industries outperforming bottom 50% by more than 2 to 1

    80% confidence
  • Tariff charges and higher costs expected to impact FMC's margins

    80% confidence
  • Cardinal Health has delivered positive earnings surprises in each of the past 14 quarters with trailing four-quarter average surprise of over 9%

    80% confidence
  • JPMorgan aims to lift its share of U.S. retail deposits through branch density

    80% confidence
  • Weaker prices due to competition for key portfolio products expected to continue weighing on FMC sales

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com